Drug Trial Radar · NCT03599791
DYmista NAsal Spray in CHInese Patients
Last checked: Nov 19, 2026Latest source record: Feb 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
900
Actual
Start
Jun 29, 2018
Primary completion
Sep 24, 2019
Study completion Sep 24, 2019
Sponsor
- Lead sponsor
- MEDA Pharma GmbH & Co. KGIndustry
- Sponsor type
- Industry
- First posted
- Jul 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase III clinical study to assess the efficacy and safety of Dymista® Nasal Spray in comparison to Azep® nasal spray and Flixonase® nasal spray in Chinese patients aged ≥ 12 years with moderate-to-severe allergic rhinitis/rhinoconjunctivitis.
Conditions
- Allergic Rhinitis
Interventions
Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUATDrug
Dymista Nasal spray suspension
Azelastine Hydrochloride 0.137 MG/ACTUATDrug
AZEP Nasal spray solution
Fluticasone Propionate 0.05 MG/ACTUATDrug
Fluticasone propionate nasal spray suspension
Primary outcomes
What the sponsor says the trial is designed to measure.
- Combined 12-hour rTNSS (AM + PM)Time frame: 14 days
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site 2
Beijing, Beijing Municipality, China
Investigational Site 3
Beijing, Beijing Municipality, China
Investigational Site 4
Beijing, Beijing Municipality, China
Investigational Site 5
Beijing, Beijing Municipality, China
Investigational Site
Chongqing, Chonqing, China
Investigational Site 1
Beijing, Dongcheng District, China
Investigational Site 1
Guangzhou, Guangdong, China
Investigational Site 2
Guangzhou, Guangdong, China
Investigational Site 1
Wuhan, Hubei, China
Investigational Site 2
Wuhan, Hubei, China
Investigational Site
Changsha, Hunan, China
Investigational Site
Nanchang, Jiangxi, China
Investigational Site
Changchun, Jilin, China
Investigational Site
Tonghua, Jilin, China
Investigational Site
Yanbian, Jilin, China
Investigational Site
Jining, Jining, China
Investigational Site
Dalian, Liaoning, China
Investigational Site
Nanjing, Nanjing, China
Investigational Site 1
Qingdao, Shandong, China
Investigational Site 2
Qingdao, Shandong, China
Investigational Site
Yantai, Shangdong, China
Investigational Site
Zibo, Shangdong, China
Investigational Site
Shanghai, Shanghai Municipality, China
Investigational Site
Changzhi, Shanxi, China
Investigational Site
Taiyuan, Shanxi, China
Investigational Site 1
Xi’an, Shanxi, China
Investigational Site 2
Xi’an, Shanxi, China
Investigational Site
Chengdu, Sichuan, China
Investigational Site 1
Tianjin, Tianjin Municipality, China
Investigational Site 2
Tianjin, Tianjin Municipality, China
Investigational Site 3
Tianjin, Tianjin Municipality, China
Investigational Site 4
Tianjin, Tianjin Municipality, China
Investigational Site
Ürümqi, Xianjiang Uygur, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.